A small-molecule blocking ribonucleotide reductase holoenzyme formation inhibits cancer cell growth and overcomes drug resistance.

@article{Zhou2013ASB,
  title={A small-molecule blocking ribonucleotide reductase holoenzyme formation inhibits cancer cell growth and overcomes drug resistance.},
  author={Bingsen Zhou and Leila Su and Shuya Hu and Weidong Hu and M. L. Richard Yip and Jun Wu and Shikha Gaur and Darrin L. Smith and Yate-Ching Yuan and Timothy W. Synold and David Horne and Yun Yen},
  journal={Cancer research},
  year={2013},
  volume={73 21},
  pages={6484-93}
}
Ribonucleotide reductase (RNR) is an attractive target for anticancer agents given its central function in DNA synthesis, growth, metastasis, and drug resistance of cancer cells. The current clinically established RNR inhibitors have the shortcomings of short half-life, drug resistance, and iron chelation. Here, we report the development of a novel class of effective RNR inhibitors addressing these issues. A novel ligand-binding pocket on the RNR small subunit (RRM2) near the C-terminal tail… CONTINUE READING
16 Citations
41 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 16 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 41 references

inventors; City of Hope, assignee. Ribonucleotide Reductatse Inhibitors and Methods of Use

  • Y Yen, D Horne, Y-C Yuan, B-S Zhou, AL Perkin Harki, L Su
  • United States patent 7956076
  • 2011
Highly Influential
3 Excerpts

Site-specific replacement

  • MR Seyedsayamdost, J. Stubbe
  • J Am Chem Soc. 2006;128:2522-3
  • 2013
1 Excerpt

Similar Papers

Loading similar papers…